Skip to search formSkip to main contentSkip to account menu

LY2334737

Known as: Gemcitabine Prodrug LY2334737 
An orally available valproic acid prodrug of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
SummaryBackground This Phase 1b study aimed to determine the recommended Phase 2 dose of LY2334737, an oral pro-drug of… 
Review
2014
Review
2014
  • G. Peters
  • Nucleosides, nucleotides & nucleic acids
  • 2014
  • Corpus ID: 205855349
Antimetabolites are the most widely used and most efficacious group of anticancer drugs. Antimetabolites are also the oldest… 
Highly Cited
2013
Highly Cited
2013
Purpose: The oral prodrug of gemcitabine LY2334737 is cleaved systemically to gemcitabine; the mechanism responsible for… 
2013
2013
LY2334737, an oral prodrug of gemcitabine, is cleaved in vivo, releasing gemcitabine and valproic acid. Oral dosing of mice… 
2013
2013
PurposeLY2334737 is an oral gemcitabine prodrug. This Phase I study assessed the safety and tolerability of LY2334737 in Japanese… 
2011
2011
Purpose: LY2334737 is an orally available prodrug of gemcitabine. The objective of this study was to determine the maximum… 
2011
2011
Metronomic chemotherapy refers to the close, regular administration of conventional chemotherapy drugs at relatively low…